Endonovo Therapeutics, Inc. (Endonovo), an innovative biotechnology company developing bioelectronics-based products and therapies for regenerative medicine, has received a Notice of Allowance from the Us Patent and Trademark Office (USPTO) for a patent application entitled "Biological Molecules Produced by Electromagnetically Stimulating Living Mammalian Cells."

The patent application covers the production of biological molecules, including growth factors and cytokines in adult stem cells using the company's proprietary technologies. This Notice of Allowance concludes substantive examination of the patent application and is expected to result in the issuance of a US patent in the near future.

The company has added this technology to its patent licensing program as it begins to pursue potential revenue producing applications of its portfolio of intellectual property.

Endonovo Chairman and CEO, Alan Collier commented, "we are excited about the issuance of this patent covering the production of biological molecules from adult stem cells, which can be used to produce human proteins." Conventional methods of protein production include recombinant techniques used with bacteria or CHO cells.

According to Thomson Reuters, the biologics sector is set for an unprecedented level of activity as US companies have rapidly increased their biologics development during the past five years. The market for next-generation biologics is estimated to reach a value of $30 billion by 2024, according to Visiongain. These next-generation biologics will seek to address shortcomings in current therapies, including inconvenient dosing and potential side-effects.

"Some applications from this technology include the production of biomolecules for research purposes or the potential production of next-generation biologics. "We are interested in potentially licensing this technology or partnering with a larger pharmaceutical/drug company to develop it," concluded Collier.